score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		SC_9103	SC_9103-Tumor	
Putatively Actionable	Preclinical		Preclinical	Copy Number	AURKA	Amplification				0.0	0.0		Putatively Actionable	Danusertib	Targeted therapy	Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).	Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.	https://doi.org/10.1158/2159-8290.CD-11-0130							Putatively Actionable	0.0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153	0				AURKA Amplification		SC_9103	SC_9103-Tumor	
Investigate Actionability - High	FDA-Approved			Somatic Variant	FGFR3	Missense	p.R622H	0.0126	396.0	0.0	0.0		Investigate Actionability - High	Erdafitinib	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Balversa [package insert]. Horsham, PA: Janssen Products, LP; 2019.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf												0	0.0	0.0	0.0	FGFR3 p.R622H (Missense)		SC_9103	SC_9103-Tumor	SC_9103-Normal
Investigate Actionability - High			Clinical evidence	Somatic Variant	STAG2	Splice Site	p.R298C	0.7333	135.0	0.0	0.0														Investigate Actionability - High	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	82.0	0.7805	1.0	STAG2 p.R298C (Splice Site)		SC_9103	SC_9103-Tumor	SC_9103-Normal
Investigate Actionability - High			Clinical evidence	Copy Number	RB1	Deletion				0.0	0.0														Investigate Actionability - High	0.0	Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				RB1 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Somatic Variant	MLH1	Missense	p.R84W	0.0149	336.0	0.0	0.0																			0	0.0	0.0	0.0	MLH1 p.R84W (Missense)		SC_9103	SC_9103-Tumor	SC_9103-Normal
Biologically Relevant				Copy Number	AKT3	Deletion				0.0	0.0																			0				AKT3 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	MSH6	Deletion				0.0	0.0																			0				MSH6 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	MSH2	Deletion				0.0	0.0																			0				MSH2 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	EPCAM	Deletion				0.0	0.0																			0				EPCAM Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	GATA3	Deletion				0.0	0.0																			0				GATA3 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																			0				ROS1 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	EML4	Deletion				0.0	0.0																			0				EML4 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	KRAS	Deletion				0.0	0.0																			0				KRAS Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Copy Number	ETV6	Deletion				0.0	0.0																			0				ETV6 Deletion		SC_9103	SC_9103-Tumor	
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH6 Deletion, MSH2 Deletion, MSH3 p.63_64insAAP (Insertion)																							0				Supporting variants: MSH6 Deletion, MSH2 Deletion, MSH3 p.63_64insAAP (Insertion)		SC_9103		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.688																							0				COSMIC Signature 1 (69%)		SC_9103		
Biologically Relevant				Mutational Signature	COSMIC Signature 15		0.312																							0				COSMIC Signature 15 (31%)		SC_9103		
